comparemela.com
Latest Breaking News On - Critical area pathology - Page 1 : comparemela.com
TACE Plus Durvalumab and Bevacizumab Could Alter SOC in Embolization-Eligible, Unresectable HCC
Riccardo Lencioni, MD, discusses how TACE, durvalumab, and bevacizumab, could represent a new standard of care in embolization-eligible HCC.
Italy
Riccardo-lencioni
Department-of-surgery
Cancers-symposium
Critical-area-pathology
Riccardo-lencioni
D
Chemoembolization-tace-
Urvalumab-imfinzi-
Nd-bevacizumab-avastin-
Hepatocellular-carcinoma
Hcc
Imfinzi, Avastin, TACE May 'Set a New Standard of Care' in Liver Cancer
Adding Imfinzi and Avastin to transarterial chemoembolization led to a 23% reduction in the risk of progression or death in patients with liver cancer.
Italy
Japan
Imfinzi-avastin
Riccardo-lencioni
Department-of-surgery
Critical-area-pathology
Asco-gastrointestinal-cancers-symposium
Liver-cancer
Durvalumab and Bevacizumab Plus TACE Improves PFS in Embolization-Eligible, Unresectable HCC
PFS was significantly improved with durvalumab plus bevacizumab and TACE vs TACE alone in patients with unresectable HCC eligible for embolization.
Italy
Japan
Riccardo-lencioni
Department-of-surgery
Critical-area-pathology
Druvalumab-and-bevacizumab-plus-tace
Dotace
Hcc
Hepatocellular-carcinoma
Gastrointestinal-cancer
Gi-cancer
Asco-gi
vimarsana © 2020. All Rights Reserved.